Скачать или смотреть Indian Biotech's 2025 Rollercoaster Challenges & Solutions 4K

🚨 Indian Biotechnology Faces Geopolitical and Financial Headwinds in August 2025
Dear Indian Biotechnology Entrepreneurs,
India’s biotech sector—once poised to lead the global biosimilar and vaccine landscape—is navigating a rough patch.
🔺 US Reciprocal Tariffs on Indian biotech exports (up to 50%) have disrupted biosimilar shipments, CRAMS, and clinical trial collaborations.
🔺 Cross-border tensions and global tech nationalism have halted funding, increased cost of reagents, and triggered a financing crunch for over 3,000+ startups and MSMEs.
Yet, India’s biotech fundamentals remain robust:
✔️ ₹11.29 Lakh Cr bioeconomy size in 2024
✔️ 6,000+ startups; 665 FDA-approved plants
✔️ Leading in biosimilars, vaccines, BT cotton & stem cell therapy
✔️ Government support via BioE3 Policy, Bio-RIDE, and ₹2,251 Cr DBT allocation in FY25
But liquidity is now the sector’s single biggest threat.
That’s where Bespoke Financials steps in—with non-dilutive, fast-disbursing, and tailor-made working capital support.
🔹 Up to ₹10 Cr – Collateral-free Working Capital
🔹 Up to ₹20 Cr – Supply Chain Finance
🔹 $5M – Export & Import Finance
🔹 ₹15 Cr – Emerging Corporate Facilities
🔹 Equity-Linked Working Capital – ₹25 Cr+
🔹 Procurement-backed finance for reagents & diagnostics
🔹 Special Agri-Biotech & Merchant Cash Advance options
💬 “We couldn’t meet US export deadlines due to the new tariffs. Bespoke stepped in with export finance in 7 days!” – CEO, Ahmedabad-based biosimilar exporter
💬 “Bespoke’s working capital saved our vaccine R&D after delayed VC funding.” – Founder, Bengaluru-based startup
With the sector aiming for US$ 300 Billion by 2030, timely capital access will decide the winners.
📞 Let’s power your innovation through adversity.
👉 Call: 8825681684
📧 Email: [email protected]
🌐 Visit: www.bespokefinancials.com
Bespoke Financials — Empowering India’s Biotechnology Innovators Since 2016.
#BiotechIndia #Bioeconomy #Biosimilars #BiotechFinance #WorkingCapital #BespokeFinancials #MakeInIndia #BioE3Policy #StartupIndia #BiotechInnovation #StemCells #Biopharma #ExportFinance #MedTech #KPSGhiri